PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month ...
Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...
PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...